RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
965. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann
Pharmacother 35: 908-917, 2001
966. Blum CB. Effects of sirolimus on lipids in renal allograft recipients:
an analysis using the Framingham risk model. Am J
Transplant 2: 551-559, 2002
967. Asberg A, Hartmann A Fjeldsa E, Bergan S, Holdaas H.
Bilateral pharmacokinetic interaction between cyclosporine
A and atorvastatin in renal transplant recipients. Am J
Transplant 1: 382-386, 2001
968. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R,
Boddaert M, y cols. Accumulation of lovastatin, but not pravastatin,
in the blood of cyclosporine treated kidney graft
patients after multiple doses. Clin Pharmacol Ther 62: 311-
321, 1997
969. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil
considerably increase serum simvastatin and simvastatin
acid concentrations. Clin Pharmacol Ther 1998; 64:
177-182, 1998
970. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on
the pharmacokinetics of atorvastatin. Clin Pharmacol Ther
64: 58-65, 1998
971. Mazzu AL, Lasseter KC, Shamblem EC, Agarwal V, Lettieri J,
Sundaresen P. Itraconazole alters the pharmacokinetics of
atorvastatin to a greater extent tham either cerivastatin or
pravastatin. Clin Pharmacol Ther 68: 391-400, 2000
972. Pasternak R, Smith S, Grundy S, y cols. ACC/AHA/NHLBI
Clinical Advisory on the use and safety of statins. J Am Coll
Cardiol 40: 567-572, 2002
973. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam
MB y cols. Gemfibrozil for the secondary prevention of
coronary heart disease in men with low levels of high-density
lipoprotein cholesterol. Veterans Affairs High-Density
Lipoprotein Cholesterol Intervention Trial Study Group.N
Engl J Med 341: 410-418, 1999
974. Anderson P, Norbeck HE. Clinical pharmacokinetic of bezafibrate
in patients with impaired renal function. Eur J Clin
Pharmacol 21:209-214, 1981
975. Desager JP, Costermans J, Verberckmoes R, Harvengt C.
Effect of hemodialysis on plasma kinetics of fenofibrate in
chronic renal failure. Nephron 31: 51-54, 1982
976. Evans JR, Forland SC, Cutler RE. The effect of renal function
on the pharmacokinetics of gemfibrozil. J Clin Pharmacol
27: 994-1000, 1987
977. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt
D, Goldberg D y cols. Poly allylamine hydrochloride
(Renagel): A noncalcemic phosphate binder for the treatment
of hyperphosphatemia in chronic renal failure. Am J
Kidney Dis 29: 66-71, 1997
978. Braunlin W, Sorbo E, Guo A, Apruzzese W, Xu Q, Hook P, y
cols. Bile acid binding to sevelamer HCl. Kidney Int 62:
611-619, 2002
979. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the
progresión of coronary and aortic calcification in hemodyalisis
patients. Kidney Int 62: 245-252, 2002
980. Soroka N, Silverberg DS, Greemland M, Birk Y, Blum M, Peer
G, y cols. Comparison of a vegetable basd (soya) and an animal
based low protein diet in predialysis chronic renal failure
patients. Nephron 79: 173-180, 1998
981. Khajehdehi P. Effect of vitamins on the lipid profile of
patients on regular hemodialysis. Scand J Urol Nephrol 34:
62-66, 2000
982. Khajehdehi P. Lipid lowering effect of polyunsaturated fatty
acids in hemodialysis patients. J Ren Nutr 10: 191-195,
2000
983. Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz
LA, y cols. Multicenter trial of L-carnitine in maintenance
hemodialysis patients. Carnitine concentrations and lipid
effects. in renal transplantation . Kidney Int 38: 904-911, 1990.
984. Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D,
Tillman M, y cols. Delayed omega-3 fatty acid supplements
in renal transplantation. A double blind placebo controlled
study. Transplantation 59: 352-356, 1995
985. Urakaze M, Hamazaki T, Yano S, Kashiwabara H, Oomori K,
Yokoyama T. Effect of fish oil concentrate on risk factors of
cardiovascular complications in renal transplantation.
Transplant Proc 21: 2134-2136, 1989
986. Ingram AJ, Parbtani A, Churchill DN. Effects of two low flux
cellulose acetate dialysers on plasma lipids and lipoproteins.
A cross over trial. Nephrol Dial Transplant 13: 1452-1457,
1998
987. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW.
Improvement of plasma lipoprotein profile during high flux
dialysis. J Am SocNephrol 3: 1409-1415, 1993
988. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H,
Koomans HA. High flux dialysis membranes improve lipid
profile in chronic hemodialysis patients. J Am Soc Nephrol
5: 1703-1708,1995.
989. Goldberg IJ, Kaufman AM, Lavarias VA, Vanni-Reyes T, Levin
NW. High flux dialysis membranes improve plasma lipoprotein
profiles in patients with end stages renal disease.
Nephrol Dial Transplant 11 (suppl 2): 104-107, 1996.
990. The USRDS diálisis Morbidity and Mortality Study: Wave 2:
United States Renal Data System. Am J Kidney Dis 30 (suppl
1): S67-S85, 1997
991. Prichard S. Coronary artery disease in end stage renal disease:
Risk factors and treatment strategies. J Jpn Soc Dial Ther
33: 159-164, 2000
992. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR,
Deckelbaum RJ, y cols. AHA Dietary Guidelines: Revision
2000: A Statement for healthcare professionals from the
Nutrition Committee of the American Heart Association.
Circulation 102: 2284-2299, 2000
993. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S,
Kris-Etherton PM y cols. Effects of the Nacional Colesterol
Education Program´s Step I and Step II dietary intervention
program on cardiovascular disease risk factors: A metaanalysis.
Am J Clin Nutr 69: 632-646, 1999.
994. Physical activity and cardiovascular health. NIH Consensus
Development Panel on Physical Activity and Cardiovascular
Health. JAMA 276: 241-246, 1996
995. National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (K/DOQI) Clinical Practice Guidelines for
Nutrition in Chronic Renal Failure. Am J Kidney Dis 35
(suppl 2): S1-S140, 2000
996. Castaneda C, Grossi L, Dweyer J. Potential benefits of resitance
exercise training on nutritional status in renal failure. J
Ren Nutr 8: 2-10, 1998.
997. McCullough PA: Cardiorenal risk: an important clinical
intersection. Rev.Cardiovasc.Med. 3:71-76, 2002.
998. Rabelink TJ: Cardiovascular risk in patients with renal disease:
treating the risk or treating the risk factor? Nephrol. Dial.
Transplant. 19:23-26, 2004.
217